Basit öğe kaydını göster

dc.contributor.authorOhno, T
dc.contributor.authorInoue, M
dc.contributor.authorOgihara, Y
dc.contributor.authorSaracoglu, I
dc.date.accessioned2019-12-16T10:09:38Z
dc.date.available2019-12-16T10:09:38Z
dc.date.issued2002
dc.identifier.issn0918-6158
dc.identifier.urihttps://doi.org/10.1248/bpb.25.666
dc.identifier.urihttp://hdl.handle.net/11655/19936
dc.description.abstractWe examined the antimetastatic effect of acteoside, a phenylethanoid glycoside widely distributed In the plant kingdom, on lung metastasis using a mouse model injected with B16 melanoma cells intravenously. Male C57BL/6 mice were injected intravenously with 2x10(5) of B16 melanoma cells, while acteoside at a dose of 50 mg/kg was administered intraperitoneally every other day from 13 d before B16 melanoma cell injection until all mice had succumbed to the metastatic tumor burden in the lung. Administration of acteoside prolonged survival time significantly and the average survival time was 63.3+/-3.4d compared with 52.1+/-2.5d in control mice. This result suggests that acteoside showed suppressive effect on lung metastasis of B16 melanoma cells.
dc.language.isoen
dc.publisherPharmaceutical Soc Japan
dc.relation.isversionof10.1248/bpb.25.666
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPharmacology & Pharmacy
dc.titleAntimetastatic Activity of Acteoside, A Phenylethanoid Glycoside
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalBiological & Pharmaceutical Bulletin
dc.contributor.departmentFarmakognozi
dc.identifier.volume25
dc.identifier.issue5
dc.identifier.startpage666
dc.identifier.endpage668
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster